Mental Health Clinics in Fairmont, NC Accepting Medicare
8 Mental Health Clinics found. Showing 1 - 8
 Therapeutic Behavioral Healthcare Services Counselor Medicare: Not Enrolled in Medicare Practice Location: 302 N Main St, Fairmont, NC 28340 Phone: 910-628-5655 |
Life Changing Behavioral Health Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 314 S Main St, Fairmont, NC 28340 Phone: 910-628-9091 Fax: 910-628-9093 |
Life Changing Behavioral Health Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 304 S Main St, Fairmont, NC 28340 Phone: 910-628-6476 Fax: 910-628-6531 |
South Robeson Medical Center Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 1212 S Walnut St, Fairmont, NC 28340 Phone: 910-628-6711 Fax: 910-628-5735 |
Pathways Therapeutic Group, Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 2268 Marion Stage Rd, Fairmont, NC 28340 Phone: 704-307-3130 |
A Great Day Enrichment Center Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1909 Horne Camp Rd, Fairmont, NC 28340 Phone: 910-628-7115 |
Life Changing Behavioral Health Services Psychiatry & Neurology - Psychosomatic Medicine Medicare: Not Enrolled in Medicare Practice Location: 314 S Main St, Fairmont, NC 28340 Phone: 910-628-6476 Fax: 910-628-6531 |
Life Changing Behaviral Health Services Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 314 S Main St, Fairmont, NC 28340 Phone: 910-628-9091 Fax: 910-628-9093 |
News Archive
Spectrum receives FDA approval for FUSILEV to treat colorectal cancer
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.
Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010
Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.
Insulin resistance largely undetected in non-diabetic patients with Parkinson's disease
Almost two-thirds of non-diabetic patients with Parkinson's disease may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson's Disease.
Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry
Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical industry.
› Verified 6 days ago